We report a patient without known preexisting liver disease who presented with hepatopulmonary syndrome (HPS) due to aberrant intrahepatic portal venous development leading to portosystemic shunting. Liver transplantation resulted in resolution of portal hypertension and HPS and sildenafil was safely tolerated in the treatment of persistent fatigue and hypoxemia. Twelve months later, patient has normal allograft function and has returned to normal activity.
CosardereliogluCCosarAMGurakarMDagherNGurakarA.Hepatopulmonary syndrome and liver transplantation: a recent review of the literature. J Clin Transl Hepatol. 2016;
4(1):47–53.
2.
Al-HussainiATaylorRMSamynM, et al.
Long-term outcomes and management of hepatopulmonary syndrome in children. Pediatr Transplant. 2010;
14(2):276–282.
3.
MistinovaJValacsaiFVargaI.Congenital absence of the portal vein—case report and a review of literature.Clin Anat. 2010;
23(7):750–758.
LemoineCNilsenABrandtKMohammadSMelin-AldanaHSuperinaR.Liver histopathology in patients with hepatic masses and the Abernethy malformation. J Pediatr Surg. 2019;
54(2):266–271.
6.
De VitoCTyraskisADavenportMThompsonRHeatonNQuagliaA.Histopathology of livers in patients with congenital portosystemic shunts (Abernethy malformation): a case series of 22 patients.Virchows Arch. 2019;
474(1):47–57.
7.
McLinVAFranchi-AbellaSDebrayD, et al.
Congenital portosystemic shunts: current diagnosis and management.J Pediatr Gastroenterol Nutr. 2019;
68(5):615–622.
8.
VallaDCCazals-HatemD.Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts.Virchows Arch. 2018;
473(1):3–13.
9.
BaigesATuronFSimon-TaleroM, et al.
Congenital extrahepatic portosystemic shunts (abernethy malformation): an international observational study. Hepatology. 2020;71(2):658--669. doi:10.1002/hep.30817
10.
LejealleCParadisVBrunoO, et al.
Evidence for an association between intrahepatic vascular changes and the development of hepatopulmonary syndrome.Chest. 2019;
155(1):123–136. doi:10.1016/j.chest.2018.09.017
11.
HartlebMGutkowskiKMilkiewiczP.Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension.World J Gastroenterol. 2011;
17(11):1400–1409.
BesmondCVallaDHubertL, et al.
Mutations in the novel gene FOPB are associated with familial autosomal dominant and non-familial obliterative portal venopathy.Liver Int. 2018;
38(2):358–364.
14.
AggarwalSFielMISchianoTD.Obliterative portal venopathy: a clinical and histopathological review.Dig Dis Sci. 2013;
58(10):2767–2776.
15.
NayakNCRamalingaswamiV.Obliterative portal venopathy of the liver. Associated with so-called idiopathic portal hypertension or tropical splenomegaly.Arch Pathol. 1969;
87(4):359–369.
16.
EmreSArnonRCohenEMorottiRAVaysmanDShneiderBL.Resolution of hepatopulmonary syndrome after auxiliary partial orthotopic liver transplantation in Abernethy malformation. A case report.Liver Transpl. 2007;
13(12):1662–1668.
17.
ChungSLeeKChangSAKimDK.Aggravation of hepatopulmonary syndrome after sildenafil treatment in a patient with coexisting portopulmonary hypertension.Korean Circ J. 2015;
45(1):77–80.
18.
TurgeonRDHussainiTPartoviN, et al.
Response to sildenafil in a patient with coexisting post-liver transplant portopulmonary hypertension and hepatopulmonary syndrome. Exp Clin Transplant. 2017;
15(6):693–695s.
19.
ZhangJLuoBTangL, et al.
Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome.Gastroenterology. 2009;
136(6):1070–1080.
20.
BhateSRissiter-ThorntonMCooperSG, et al.
Use of sildenafil and nitric oxide in the management of hypoxemia owing to pulmonary arteriovenous fistulas after total cavopulmonary connection.J Thorac Cardiovasc Surg. 2008;
135(2):446–448.
